Effects of a germ-free environment on gut immune regulation and diabetes progression in non-obese diabetic (NOD) mice. 2011

C Alam, and E Bittoun, and D Bhagwat, and S Valkonen, and A Saari, and U Jaakkola, and E Eerola, and P Huovinen, and A Hänninen
Department of Medical Microbiology and Immunology, Kiinamyllynkatu 13, University of Turku, 20520 Turku, Finland. catharina.alam@utu.fi

OBJECTIVE Microbial factors influence the development of diabetes in NOD mice. Studies in germ-free animals have revealed important roles of microbiota in the regulation of Th17 and forkhead box P3 (FOXP3)(+) T regulatory (Treg) activation in the intestine. However, the effects of intestinal microbiota in immune regulation and diabetes development in NOD mice are still poorly understood. METHODS A colony of germ-free NOD mice was established to evaluate the effects of intestinal microbiota on regulatory immunity in the gut, and on the development of insulitis and diabetes in NOD mice. RESULTS Diabetes developed in roughly equal numbers in germ-free and specific pathogen-free NOD mice. Insulitis was accentuated in germ-free NOD mice; yet insulin preservation was unaltered. Germ-free NOD mice showed increased levels of Il17 (also known as Il17a) mRNA in the colon, and of Th17 and Th1 cells in the mesenteric and pancreatic lymph nodes, while Foxp3 mRNA and FOXP3(+) Tregs were reduced. In the islet infiltrates, FOXP3(+)CD4(+) T cells were slightly increased in germ-free mice. B cells appeared less activated in the peritoneum and were less abundant in islet infiltrates. CONCLUSIONS These results indicate that lack of intestinal microbiota promotes an imbalance between Th1, Th17 and Treg differentiation in the intestine. This imbalance is associated with accelerated insulitis, but intact recruitment of FOXP3(+) Tregs into islets, suggesting: (1) a microbial dependence of local induction of Treg in the gut and draining lymph nodes; but (2) a potentially compensatory function of naturally occurring Tregs in the islets, which may help control diabetogenic T cells.

UI MeSH Term Description Entries
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005856 Germ-Free Life Animals not contaminated by or associated with any foreign organisms. Axenic Animals,Gnotobiotics,Germfree Life,Animal, Axenic,Animals, Axenic,Axenic Animal,Germ Free Life,Gnotobiotic,Life, Germ-Free,Life, Germfree
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016688 Mice, Inbred NOD A strain of non-obese diabetic mice developed in Japan that has been widely studied as a model for T-cell-dependent autoimmune insulin-dependent diabetes mellitus in which insulitis is a major histopathologic feature, and in which genetic susceptibility is strongly MHC-linked. Non-Obese Diabetic Mice,Mice, NOD,Mouse, Inbred NOD,Mouse, NOD,Non-Obese Diabetic Mouse,Nonobese Diabetic Mice,Nonobese Diabetic Mouse,Diabetic Mice, Non-Obese,Diabetic Mice, Nonobese,Diabetic Mouse, Non-Obese,Diabetic Mouse, Nonobese,Inbred NOD Mice,Inbred NOD Mouse,Mice, Non-Obese Diabetic,Mice, Nonobese Diabetic,Mouse, Non-Obese Diabetic,Mouse, Nonobese Diabetic,NOD Mice,NOD Mice, Inbred,NOD Mouse,NOD Mouse, Inbred,Non Obese Diabetic Mice,Non Obese Diabetic Mouse

Related Publications

C Alam, and E Bittoun, and D Bhagwat, and S Valkonen, and A Saari, and U Jaakkola, and E Eerola, and P Huovinen, and A Hänninen
February 2008, Autonomic neuroscience : basic & clinical,
C Alam, and E Bittoun, and D Bhagwat, and S Valkonen, and A Saari, and U Jaakkola, and E Eerola, and P Huovinen, and A Hänninen
April 2019, Archives of toxicology,
C Alam, and E Bittoun, and D Bhagwat, and S Valkonen, and A Saari, and U Jaakkola, and E Eerola, and P Huovinen, and A Hänninen
August 1987, Experimental and clinical endocrinology,
C Alam, and E Bittoun, and D Bhagwat, and S Valkonen, and A Saari, and U Jaakkola, and E Eerola, and P Huovinen, and A Hänninen
March 1989, Clinical and experimental immunology,
C Alam, and E Bittoun, and D Bhagwat, and S Valkonen, and A Saari, and U Jaakkola, and E Eerola, and P Huovinen, and A Hänninen
October 2018, Contact dermatitis,
C Alam, and E Bittoun, and D Bhagwat, and S Valkonen, and A Saari, and U Jaakkola, and E Eerola, and P Huovinen, and A Hänninen
May 1999, Clinical and experimental immunology,
C Alam, and E Bittoun, and D Bhagwat, and S Valkonen, and A Saari, and U Jaakkola, and E Eerola, and P Huovinen, and A Hänninen
June 2019, International immunopharmacology,
C Alam, and E Bittoun, and D Bhagwat, and S Valkonen, and A Saari, and U Jaakkola, and E Eerola, and P Huovinen, and A Hänninen
May 2019, Advanced healthcare materials,
C Alam, and E Bittoun, and D Bhagwat, and S Valkonen, and A Saari, and U Jaakkola, and E Eerola, and P Huovinen, and A Hänninen
February 1988, Diabetes research (Edinburgh, Scotland),
C Alam, and E Bittoun, and D Bhagwat, and S Valkonen, and A Saari, and U Jaakkola, and E Eerola, and P Huovinen, and A Hänninen
September 1991, Clinical and experimental immunology,
Copied contents to your clipboard!